CO2021004035A2 - Ensayo de cribado de cáncer inmunogenético - Google Patents
Ensayo de cribado de cáncer inmunogenéticoInfo
- Publication number
- CO2021004035A2 CO2021004035A2 CONC2021/0004035A CO2021004035A CO2021004035A2 CO 2021004035 A2 CO2021004035 A2 CO 2021004035A2 CO 2021004035 A CO2021004035 A CO 2021004035A CO 2021004035 A2 CO2021004035 A2 CO 2021004035A2
- Authority
- CO
- Colombia
- Prior art keywords
- immunogenetic
- screening assay
- cancer screening
- developing cancer
- disclosure
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 230000002998 immunogenetic effect Effects 0.000 title 1
- 238000007423 screening assay Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/30—Detection of binding sites or motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1814361.0A GB201814361D0 (en) | 2018-09-04 | 2018-09-04 | Immunogenetic cancer screening test |
| PCT/EP2019/073478 WO2020048992A1 (en) | 2018-09-04 | 2019-09-03 | Immunogenetic cancer screening test |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021004035A2 true CO2021004035A2 (es) | 2021-07-30 |
Family
ID=63920791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0004035A CO2021004035A2 (es) | 2018-09-04 | 2021-03-30 | Ensayo de cribado de cáncer inmunogenético |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220233660A1 (he) |
| EP (1) | EP3847461A1 (he) |
| JP (1) | JP7419351B2 (he) |
| KR (1) | KR20210086611A (he) |
| CN (1) | CN113330313A (he) |
| AU (1) | AU2019333861A1 (he) |
| BR (1) | BR112021004079A2 (he) |
| CA (1) | CA3110918A1 (he) |
| CL (1) | CL2021000533A1 (he) |
| CO (1) | CO2021004035A2 (he) |
| EA (1) | EA202190671A1 (he) |
| GB (1) | GB201814361D0 (he) |
| IL (1) | IL281218A (he) |
| MA (1) | MA53542A (he) |
| MX (1) | MX2021002450A (he) |
| SG (1) | SG11202101956VA (he) |
| WO (1) | WO2020048992A1 (he) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019010459A (es) | 2017-03-03 | 2020-01-09 | Treos Bio Zrt | Vacuna. |
| MX2021002449A (es) | 2018-09-04 | 2021-08-05 | Treos Bio Ltd | Vacunas peptidicas. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US9487574B2 (en) | 2006-09-21 | 2016-11-08 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope vaccines |
| WO2015014375A1 (en) | 2013-07-30 | 2015-02-05 | Biontech Ag | Tumor antigens for determining cancer therapy |
| AU2014298504B2 (en) | 2013-07-30 | 2018-08-30 | Biontech Ag | Tumor antigens for determining cancer therapy |
| EP3369431A1 (en) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Vaccine |
| MX2019010459A (es) | 2017-03-03 | 2020-01-09 | Treos Bio Zrt | Vacuna. |
| EP3370065A1 (en) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Immunogenic peptides |
-
2018
- 2018-09-04 GB GBGB1814361.0A patent/GB201814361D0/en not_active Ceased
-
2019
- 2019-09-03 WO PCT/EP2019/073478 patent/WO2020048992A1/en active Application Filing
- 2019-09-03 MX MX2021002450A patent/MX2021002450A/es unknown
- 2019-09-03 US US17/250,722 patent/US20220233660A1/en active Pending
- 2019-09-03 SG SG11202101956VA patent/SG11202101956VA/en unknown
- 2019-09-03 EA EA202190671A patent/EA202190671A1/ru unknown
- 2019-09-03 BR BR112021004079-0A patent/BR112021004079A2/pt unknown
- 2019-09-03 EP EP19759627.3A patent/EP3847461A1/en active Pending
- 2019-09-03 CA CA3110918A patent/CA3110918A1/en active Pending
- 2019-09-03 MA MA053542A patent/MA53542A/fr unknown
- 2019-09-03 CN CN201980071003.5A patent/CN113330313A/zh active Pending
- 2019-09-03 KR KR1020217009976A patent/KR20210086611A/ko not_active Application Discontinuation
- 2019-09-03 AU AU2019333861A patent/AU2019333861A1/en active Pending
- 2019-09-03 JP JP2021512911A patent/JP7419351B2/ja active Active
-
2021
- 2021-03-03 IL IL281218A patent/IL281218A/he unknown
- 2021-03-04 CL CL2021000533A patent/CL2021000533A1/es unknown
- 2021-03-30 CO CONC2021/0004035A patent/CO2021004035A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3110918A1 (en) | 2020-03-12 |
| EP3847461A1 (en) | 2021-07-14 |
| SG11202101956VA (en) | 2021-03-30 |
| JP7419351B2 (ja) | 2024-01-22 |
| KR20210086611A (ko) | 2021-07-08 |
| WO2020048992A1 (en) | 2020-03-12 |
| BR112021004079A2 (pt) | 2021-05-25 |
| CN113330313A (zh) | 2021-08-31 |
| MA53542A (fr) | 2021-07-14 |
| EA202190671A1 (ru) | 2021-09-21 |
| IL281218A (he) | 2021-04-29 |
| JP2022500630A (ja) | 2022-01-04 |
| MX2021002450A (es) | 2021-07-15 |
| US20220233660A1 (en) | 2022-07-28 |
| AU2019333861A1 (en) | 2021-03-18 |
| CL2021000533A1 (es) | 2021-09-24 |
| GB201814361D0 (en) | 2018-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019010524A2 (es) | Plataforma de identificación de péptidos inmunogénicos basada en población | |
| CO2018010475A2 (es) | Moléculas de unión a bcma y métodos de uso de las mismas | |
| CO2021009693A2 (es) | Proteínas de unión a antígeno del receptor gamma anti-il2 | |
| CO2021004035A2 (es) | Ensayo de cribado de cáncer inmunogenético | |
| NZ743881A (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
| EA201790755A1 (ru) | Модуляция стимулирующих и нестимулирующих миелоидных клеток | |
| BR112018000696A2 (pt) | ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit? | |
| BR112017017293A2 (pt) | método para predizer modificações de aminoácidos, para selecionar e/ou classificar modificações de aminoácidos e para fornecer uma vacina e vacina | |
| BR112018070676A2 (pt) | construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos | |
| BR112018071683A2 (pt) | método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente | |
| PE20210517A1 (es) | Anticuerpos anti-hla-g y utilizacion de los mismos | |
| MX2020009861A (es) | Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos. | |
| AR110114A1 (es) | ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS | |
| CY1124069T1 (el) | Ανοσιακα κυτταρα ελαττωματικα για suv39η1 | |
| NI202000051A (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
| CO2021005207A2 (es) | Métodos de tratamiento | |
| BR112018008799A2 (pt) | método de prognóstico | |
| CY1121169T1 (el) | Αντισωμα που δεσμευει ενα γραμμικο επιτοπο ανθρωπινου ρ53 και διαγνωστικες εφαρμογες αυτου | |
| CO2021011944A2 (es) | Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer | |
| CO2021008204A2 (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso | |
| BR112017022205A2 (pt) | anticorpo anti-vegfr2 humano para terapia de câncer antiangiogênica e objetivada | |
| UY37082A (es) | Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv | |
| CO2021005234A2 (es) | Métodos de tratamiento | |
| CO2021009689A2 (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso. | |
| EA201992059A1 (ru) | Платформа для идентификации иммуногенных пептидов популяционного уровня |